文献速递免疫规划卫生政策与健康促进

随机临床试验中的年度免疫原性测量有助于揭示长期疫苗效力的异质性:一项汇总逻辑回归建模研究

Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study.
PubMed 文献 · Vaccine · 2026-03-06

疫苗研发需了解疫苗诱导保护的持续时间及不同人群的差异,但2b期和3期效力试验很少有能力评估年度效力或亚组长期保护差异。该研究应用加权横断面汇总逻辑回归模型,对两项3期试验的免疫原性亚研究进行建模,预测登革热疫苗在基线血清阴性和阳性个体、带状疱疹疫苗在≤69岁和≥70岁个体中的保护持久性。纳入时间依赖的免疫原性数据提高了时变效力估计的精确度,相比传统病例计数方法,该框架有助于揭示原本因病例数稀疏或随访有限而被掩盖的效力趋势。

要点

  • 在临床试验中收集并建模年度免疫原性数据可加速理解疫苗诱导保护的持久性。
  • 加权横断面汇总逻辑回归模型纳入时间依赖免疫原性数据可提高时变效力估计精确度。
  • 该框架无需绝对或机制性保护相关物,可揭示因病例稀疏或随访有限而掩盖的效力趋势。

核心结论

  • 在临床试验中收集并建模年度免疫原性数据,可加速理解疫苗诱导保护在亚组内和亚组间的持久性,并指导高效开发多年保护的疫苗。

研究设计与样本

  • 研究对两项3期试验的免疫原性亚研究应用加权横断面汇总逻辑回归模型,预测登革热疫苗在基线血清阴性和阳性个体、带状疱疹疫苗在≤69岁和≥70岁个体中的保护持久性。

主要发现

  • 纳入时间依赖的免疫原性数据提高了时变效力估计的精确度,相比传统病例计数方法。
  • 当时间依赖的免疫标志物对保护有足够预测性时,该框架有助于揭示原本因病例数稀疏或随访有限而被掩盖的效力趋势。

临床怎么用

  • 临床试验中可收集所有参与者、免疫原性队列或病例-队列亚研究的年度免疫原性数据,并建模以加速理解疫苗保护持久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine development requires understanding the duration of vaccine-induced protection and whether it differs across demographic groups. Phase 2b and phase 3 efficacy trials are rarely powered to assess annual efficacy or subgroup differences in long-term protection, so these attributes can remain unevaluated until years after licensure, when observational effectiveness studies become available. However, late-stage clinical trials typically collect longitudinal immunogenicity data (for established or putative correlates of protection), which could be useful for predicting vaccine efficacy over time. To address this, a weighted cross-sectionally pooled logistic regression model was applied to immunogenicity substudies from two phase 3 trials to predict the durability of protection in specific subgroups: baseline dengue seronegative and seropositive individuals for dengue vaccine, and younger (≤ 69 years) and older (≥ 70 years) individuals for zoster vaccine. Incorporating time-dependent immunogenicity data increased the precision of time-varying efficacy estimates compared with traditional case-count methods. The modeling framework extends prior immune correlate analyses that used immunogenicity measured at a single timepoint post vaccination (without requiring an absolute or mechanistic correlate of protection). When time-dependent immune markers are sufficiently predictive of protection, the framework helps reveal trends in efficacy that would otherwise be obscured by sparse case counts or limited follow-up. Collecting and modeling annual immunogenicity data in clinical trials (whether from all participants, an immunogenicity cohort, or a case-cohort substudy) can thus accelerate understanding of the persistence of vaccine-induced protection (across and within subgroups) and guide efficient development of vaccines that are protective for years.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dudášová J, Valenta Z, Măgălie A, et al. Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study. Vaccine. 2026. PMID: 41793964. doi:10.1016/j.vaccine.2026.128326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。